|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Guided Therapeutics, Inc. Successfully Completes Electrical Testing of LuViva® Advanced Cervical Scan for Edition 3 CE and Canadian Standards Association Marks
12/5/2012 11:09:45 AM
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), today announced that it has successfully completed electromagnetic compatibility testing, one of two major categories of third-party testing required to label the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, with the ISO 60601 Edition 3 CE Mark and Canadian Standards Association (CSA) Mark. "Electromagnetic compatibility testing can be the most challenging of the major certification components, and we are pleased to report our successful outcome,” said Richard Fowler, Senior Vice President of Engineering at Guided Therapeutics. “Basic safety testing, the next phase of work to be done at the third-party testing facility, is expected to be completed in the next two to three weeks.”
|
|
|
|
|
|
|
|
|
|
|